中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(7): 1570-1577

Clinical features of idiopathic non-cirrhotic portal hypertension: An analysis of 74 patients

DOI: 10.3969/j.issn.1001-5256.2023.07.010
  • a.

    Third Department of Liver Disease Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

  • b.

    Department of Medical Service, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

Incubation Program for Young and Middle-aged Talents in Beijing YouAn Hospital Affiliated to Capital Medical University (YNKTJL2021001)

More Information
  • Corresponding author: ZHANG Yuening, zyn1625@ccmu.edu.cn (ORCID: 0000-0003-2205-3413)
  • Received Date: 2022-11-30
  • Accepted Date: 2023-01-09
  • Published Date: 2023-07-20
    Abstract
  •   Objective  Idiopathic non-cirrhotic portal hypertension (INCPH) is a rare cause of portal hypertension, and this study aims to analyze the clinical features of patients with INCPH, and to assist in diagnosis and differential diagnosis.  Methods  A total of 74 patients who were hospitalized in Beijing YouAn Hospital from January 2019 to July 2022 and were diagnosed with INCPH were enrolled, and 332 patients with liver cirrhosis who were hospitalized during the same period of time were enrolled as control group. Demographic data, laboratory markers, gastroscopy, liver elasticity, pathological examination, and complications were recorded and compared between the two groups. The receiver operating characteristic (ROC) curve was used to investigate the ability of liver stiffness measurement (LSM), aspartate aminotransferase-to-platelet ratio index (APRI), and fibrosis-4 (FIB-4) in the differential diagnosis of INCPH, and the DeLong test was used to compare the area under the ROC curve (AUC). The independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups.  Results  Among the patients with INCPH, 46.55% had no obvious symptoms at disease onset and 43.24% were misdiagnosed with liver cirrhosis. Compared with the patients with liver cirrhosis, the patients with INCPH had a significantly higher proportion of patients with gastrointestinal bleeding (62.16% vs 41.27%, χ2=10.67, P < 0.01) and a significantly lower proportion of patients with moderate-to-severe ascites (16.21% vs 29.82%, χ2=34.98, P < 0.01), and there were few patients with hepatic encephalopathy. As for pathology, 89.19% (66/74) of the INCPH patients manifested as typical occlusive portal vein disease. The statistical analysis showed that compared with the patients with liver cirrhosis, the patients with INCPH had significantly better liver function parameters, MELD score, and Child-Pugh score and significantly lower LSM [9.05(7.18-12.33) vs 25.32(16.21-47.23), Z=-8.41, P < 0.01], APRI score [0.70(0.41-1.28) vs 1.35(0.80-2.39), Z=-6.21, P < 0.01], and FIB-4 index [2.99(1.62-4.81) vs 6.68(4.06-10.42), Z=-8.39, P < 0.01]. LSM, FIB-4, and APRI had a good ability in differentiating INCPH from liver cirrhosis, and in particular, LSM had an AUC of up to 0.92 (95% confidence interval: 0.87-0.96), with a sensitivity of 92.68% and a specificity of 81.60%.  Conclusion  INCPH patients tend to have an insidious onset, a relatively high incidence rate of portal hypertension-related complications, and relatively good liver function, especially the patients with LSM < 14.5 kPa. The possibility of INCPH should be considered for such patients in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association. Chinese expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022 edition)[J]. Chin J Dig Surg, 2022, 21(4): 444-455. DOI: 10.3760/cma.j.cn115610-20220223-00104.

    中华医学会外科学分会脾及门静脉高压外科学组. 门静脉高压合并肝细胞癌临床诊断与治疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21(4): 444-455. DOI: 10.3760/cma.j.cn115610-20220223-00104.
    [2]
    HUANG D, CAO JG, YE HY, et al. Occurrence and progression of hemodynamic dysfunction in cirrhotic portal hypertension[J]. Chin J Dig Surg, 2021, 20(10): 1117-1122. DOI: 10.3760/cma.j.cn115610-20210813-00394.

    黄登, 曹君贵, 叶航羊, 等. 肝硬化门静脉高压血流动力学紊乱发生及发展机制[J]. 中华消化外科杂志, 2021, 20(10): 1117-1122. DOI: 10.3760/cma.j.cn115610-20210813-00394.
    [3]
    XU JH, YU YY, XU XY. Current status of the clinical management of non-cirrhotic portal hypertension[J]. J Clin Hepatol, 2022, 38(7): 1457-1459. DOI: 10.3969/j.issn.1001-5256.2022.07.001.

    徐京杭, 于岩岩, 徐小元. 非肝硬化性门静脉高压症的临床管理现状[J]. 临床肝胆病杂志, 2022, 38(7): 1457-1459. DOI: 10.3969/j.issn.1001-5256.2022.07.001.
    [4]
    European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202. DOI: 10.1016/j.jhep.2015.07.040.
    [5]
    KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
    [6]
    WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38(2): 518-526. DOI: 10.1053/jhep.2003.50346.
    [7]
    TESHALE E, LU M, RUPP LB, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS)[J]. J Viral Hepat, 2014, 21(12): 917-920. DOI: 10.1111/jvh.12279.
    [8]
    SATO Y, REN XS, HARADA K, et al. Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies[J]. Clin Exp Immunol, 2012, 167(3): 532-542. DOI: 10.1111/j.1365-2249.2011.04530.x.
    [9]
    SCHOUTEN JN, GARCIA-PAGAN JC, VALLA DC, et al. Idiopathic noncirrhotic portal hypertension[J]. Hepatology, 2011, 54(3): 1071-1081. DOI: 10.1002/hep.24422.
    [10]
    GOEL A, ELIAS JE, EAPEN CE, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension (NCIPH)-newer insights into pathogenesis and emerging newer treatment options[J]. J Clin Exp Hepatol, 2014, 4(3): 247-256. DOI: 10.1016/j.jceh.2014.07.005.
    [11]
    de GOTTARDI A, RAUTOU PE, SCHOUTEN J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411. DOI: 10.1016/S2468-1253(19)30047-0.
    [12]
    OKUDAIRA M, OHBU M, OKUDA K. Idiopathic portal hypertension and its pathology[J]. Semin Liver Dis, 2002, 22(1): 59-72. DOI: 10.1055/s-2002-23207.
    [13]
    PULVIRENTI F, PENTASSUGLIO I, MILITO C, et al. Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies[J]. J Immunol Res, 2014, 2014: 672458. DOI: 10.1155/2014/672458.
    [14]
    GUIDO M, SARCOGNATO S, SACCHI D, et al. Pathology of idiopathic non-cirrhotic portal hypertension[J]. Virchows Arch, 2018, 473(1): 23-31. DOI: 10.1007/s00428-018-2355-8.
    [15]
    EAPEN CE, NIGHTINGALE P, HUBSCHER SG, et al. Non-cirrhotic intrahepatic portal hypertension: associated gut diseases and prognostic factors[J]. Dig Dis Sci, 2011, 56(1): 227-235. DOI: 10.1007/s10620-010-1278-2.
    [16]
    CAZALS-HATEM D, HILLAIRE S, RUDLER M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis[J]. J Hepatol, 2011, 54(3): 455-461. DOI: 10.1016/j.jhep.2010.07.038.
    [17]
    VERNIER-MASSOUILLE G, COSNES J, LEMANN M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine[J]. Gut, 2007, 56(10): 1404-1409. DOI: 10.1136/gut.2006.114363.
    [18]
    SANTRA A, DAS GUPTA J, DE BK, et al. Hepatic manifestations in chronic arsenic toxicity[J]. Indian J Gastroenterol, 1999, 18(4): 152-155.
    [19]
    GUIDO M, ALVES V, BALABAUD C, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition[J]. Histopathology, 2019, 74(2): 219-226. DOI: 10.1111/his.13738.
    [20]
    MADHU K, AVINASH B, RAMAKRISHNA B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital[J]. Indian J Gastroenterol, 2009, 28(3): 83-87. DOI: 10.1007/s12664-009-0030-3.
    [21]
    NAYAK NC, JAIN D, SAIGAL S, et al. Non-cirrhotic portal fibrosis: one disease with many names? An analysis from morphological study of native explant livers with end stage chronic liver disease[J]. J Clin Pathol, 2011, 64(7): 592-598. DOI: 10.1136/jcp.2010.087395.
    [22]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
    [23]
    SEIJO S, REVERTER E, MIQUEL R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension[J]. Dig Liver Dis, 2012, 44(10): 855-860. DOI: 10.1016/j.dld.2012.05.005.
    [24]
    KHANNA R, SARIN SK. Non-cirrhotic portal hypertension - diagnosis and management[J]. J Hepatol, 2014, 60(2): 421-441. DOI: 10.1016/j.jhep.2013.08.013.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (288) PDF downloads(56) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return